Summary
A primary safety issue presented by human hematopoietic stem cells/progenitor cells (HS/PC) genetically modified by gammaretroviral or lentiviral vectors is the risk of oncogenesis. This risk is a potential consequence of either of the following events: (a) the possible unintended generation of replication-competent vector-derived viruses (replication-competent retrovirus, RCR; replication-competent lentivirus, RCL) leading to neoplasia due to RCR/RCL infection of target and nontarget cells in vivo, or (b) intended vector integration in the chromosomal DNA of the target somatic cells leading to neoplasia due to insertional mutagenesis. These risks should be addressed in nonclinical and clinical studies. In the US and the EU, a combination of regulations and guidance documents are available to investigators and sponsors of gene therapy clinical trials. Guidance documents provide a facile way to adapt regulatory recommendations, in line with the changing state of the art in medical science. In the field of retroviral vectors, a number of innovations are being tested in nonclinical or clinical investigations, and each of these will raise their own regulatory issues. Some recent examples of these types of innovations include development of novel vector structures to minimize risks associated with vector integration, such as lentiviral vectors currently used in clinical trials for HS/PC modification that have been designed with deletions of the strong retroviral enhancer associated with oncogenesis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hacein-Bey-Abina, S., et al. (2003) A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348 (3) : 255 – 256.
Hacein-Bey-Abina, S., et al. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 (5644) : 415 – 419.
Donahue, R.E., et al. (1992) Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J. Exp. Med. 176 : 1125 – 1135.
Vanin, E.F., et al. (1994) Characterization of replication-competent retroviruses from non-human primates with virus-induced lymphomas and observations regarding the mechanism of oncogenesis. J. Virol. 68 (7) : 4241 – 4250.
Purcell, D.F.J., et al. (1996) An array of murine leukemia virus-related elements is transmitted and expressed in a primate recipient of retroviral gene transfer. J. Virol. 70 (2) : 887 – 897.
Kiermer, V., et al. (2005) Report from the Lentivirus Vector Working Group: issues for developing assays and reference materials for detecting replication-competent lentivirus in production lots of lentivirus vectors. BioProcessing 4 (2) : 39 – 42.
Fuchs, B., et al. (2003) Ewing's sarcoma and the development of secondary malignancies. Clin. Orthop. Relat. Res. 415: 82–89.
Li, Z., et al. (2002) Murine leukemia induced by retroviral gene marking. Science 296 : 497.
Acknowledgments
We thank the ICH Gene Therapy Discussion Group, the EMEA/ CHMP Gene Therapy Working Party, the CBER/FDA Office of Cellular, Tissues, and Gene Therapy and the Division of Medical Biotechnology of the Paul-Ehrlich-Institut in Langen, Germany, for helpful discussion and continuous inspiration on regulatory work in gene and cell therapy.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Wilson, C.A., Cichutek, K. (2009). The US and EU Regulatory Perspectives on the Clinical Use of Hematopoietic Stem/Progenitor Cells Genetically Modified Ex Vivo by Retroviral Vectors. In: Baum, C. (eds) Genetic Modification of Hematopoietic Stem Cells. Methods In Molecular Biology™, vol 506. Humana Press. https://doi.org/10.1007/978-1-59745-409-4_32
Download citation
DOI: https://doi.org/10.1007/978-1-59745-409-4_32
Publisher Name: Humana Press
Print ISBN: 978-1-58829-980-2
Online ISBN: 978-1-59745-409-4
eBook Packages: Springer Protocols